HUMAN AMYLOID IMAGING CONFERENCE
HAI 2019 will continue to emphasize ample lively discussion of core controversies such as: what does the presence of brain amyloid mean, how should it be measured, how does it change, and what does it portend? The discussions primarily will spring from brief presentations by active investigators who will report unpublished, cutting-edge research in human imaging of amyloid-beta and/or other biomarkers that pertain to Alzheimer’s-related disease.
To assemble HAI, only the most recent, important work, abstract submissions and peer-reviews will be accepted. The 2018 meeting drew more than 400 attendees and showcased 130 posters from research groups spanning North America, Europe, East Asia, and Australia. Research reports are complemented at HAI by Keynote presentations that are intended to cross disciplines and provide perspectives from neuropathology, neurochemistry, psychology, neurology, molecular imaging, clinical trials and biomarker research.
|Preise werden noch bekannt gegeben|
|Preise werden noch bekannt gegeben||$ 0,00|